» Articles » PMID: 31815121

Prevalence and Associated Factors of Metabolic Syndrome Among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2019 Dec 10
PMID 31815121
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Globally, the prevalence of metabolic syndrome (MetS) and its components which are the major cardiovascular disease (CVD) risk factors, is higher among patients with severe mental illness (SMI) compared to the general population. This is mainly due to the deleterious lifestyles characterized by physical inactivity, excessive alcohol consumption, smoking, and unhealthy diets common among patients with SMI as well as due to cardiometabolic effects of psychotropic medications. Despite these conditions being highly prevalent among patients with SMI, little attention is given to these conditions during routine reviews in the mental health clinics in most low-income countries including Uganda. The main objective of this study was to determine the prevalence and associated factors of MetS among patients with SMI at Mbarara Regional Referral Hospital (MRRH), a tertiary hospital in southwestern Uganda. Through a cross-sectional study at the mental health clinic of the hospital, we recruited 304 patients with SMI and evaluated them for MetS using the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) criteria. We defined the prevalence of MetS as the proportion of patients meeting the NCEP ATP III criteria. We used logistic regression to evaluate associations between MetS and independent variables. We included a total of 302 (44.37% male, 55.63% female) patients with a diagnosis of SMI in the analysis. The prevalence of MetS was 23.51% (95% CI 18.84-28.71). At multivariable logistic regression, age >40 years and long duration of mental illness (>10 years) were significantly associated with MetS. The prevalence of MetS is high among patients with psychiatric disorders, and thus metabolic screening, especially among the high-risk groups, is critical.

Citing Articles

Metabolic Syndrome and Its Associated Factors Among Patients With Schizophrenia Treated With Second-Generation Antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia.

Beyene M, Teferra S, Fenta T Cureus. 2024; 16(9):e69065.

PMID: 39391415 PMC: 11465686. DOI: 10.7759/cureus.69065.


Metabolic Syndrome and Its Component Factors Among Corporate Company Employees in Kampala Uganda.

Kyeyune J, Mchiza Z, Bashir M, Ingabire P, Githinji F, Nakaggwa F Res Sq. 2024; .

PMID: 39315263 PMC: 11419266. DOI: 10.21203/rs.3.rs-4907042/v1.


Elevated thyroid stimulating hormone and metabolic syndrome risk in patients with first-episode and drug-naïve major depressive disorder: a large-scale cross-sectional study.

Zhang Q, Dong G, Zhu X, Cao Y, Zhang X BMC Psychiatry. 2024; 24(1):380.

PMID: 38773550 PMC: 11110191. DOI: 10.1186/s12888-024-05847-4.


Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis.

Bowo-Ngandji A, Kenmoe S, Ebogo-Belobo J, Kenfack-Momo R, Takuissu G, Kengne-Nde C PLoS One. 2023; 18(7):e0289155.

PMID: 37498832 PMC: 10374159. DOI: 10.1371/journal.pone.0289155.


Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study.

Tsima B, Opondo P, Mosepele M, Mautle E, Bilker W, Gross R BMC Cardiovasc Disord. 2022; 22(1):515.

PMID: 36460970 PMC: 9717503. DOI: 10.1186/s12872-022-02939-5.


References
1.
Meyer J, Mao Y, Pikalov A, Cucchiaro J, Loebel A . Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015; 30(6):342-50. PMC: 4593468. DOI: 10.1097/YIC.0000000000000091. View

2.
Vancampfort D, Vansteelandt K, Correll C, Mitchell A, De Herdt A, Sienaert P . Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013; 170(3):265-74. DOI: 10.1176/appi.ajp.2012.12050620. View

3.
Gardner-Sood P, Lally J, Smith S, Atakan Z, Ismail K, Greenwood K . Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015; 45(12):2619-29. PMC: 4531468. DOI: 10.1017/S0033291715000562. View

4.
Hasnain M, Fredrickson S, Vieweg W, Pandurangi A . Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10(3):209-16. DOI: 10.1007/s11892-010-0112-8. View

5.
Kalantari P, Harandi O, Hankey P, Henderson A . HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. J Immunol. 2008; 181(2):1548-55. PMC: 2536764. DOI: 10.4049/jimmunol.181.2.1548. View